Release Date: September 25, 2025
Expiration Date: September 25, 2026
Activity Overview
The characterization of the RAS oncogenes and mutations that lead to their activation has been one of the seminal discoveries in oncology. However, actively exploiting these proteins as a therapeutic strategy in solid tumor oncology has been made possible only recently with the incorporation of highly specific inhibitors. More recently, novel RAS-directed strategies have been developed, with the potential to address a much wider range of RAS alterations.
This educational meeting, provided in conjunction with the 2025 International Symposium of Gastrointestinal Oncology, brings together world-leading faculty in the management of gastrointestinal cancers to discuss the current landscape of agents targeting RAS family members, as well as novel strategies in development with the potential to impact a much broader range of alterations.
This educational activity is an archive of the live virtual symposium held on September 12, 2025.
Target Audience
This educational activity is directed toward medical oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in gastrointestinal (GI) oncology. Other health care professionals interested in the treatment of these malignancies are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the current and emerging role of RAS-directed therapies across GI malignancies
- Identify appropriate molecular profiling tests to individualize patient treatment therapies for patients with GI cancers
- Analyze efficacy and safety data from RAS-directed clinical trials and their impact on the management of GI cancers
- Implement optimal approaches for incorporating innovative RAS therapies into the treatment of GI cancers where approved
- Apply proactive strategies for monitoring and managing treatment-related toxicities in patients receiving RAS-directed therapies for GI cancers
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here